Literature DB >> 31255795

Reliable Gene Expression Profiling from Small and Hematoxylin and Eosin-Stained Clinical Formalin-Fixed, Paraffin-Embedded Specimens Using the HTG EdgeSeq Platform.

Zhenhao Qi1, Lisu Wang2, Keyur Desai1, John Cogswell1, Mark Stern3, Byron Lawson3, Sid P Kerkar1, Patrik Vitazka1.   

Abstract

Clinical biomarker studies are often hindered by the scarcity or suboptimal quality of biological specimens. EdgeSeq, a transcriptomics analysis platform, combines quantitative nuclease protection assay technology with next-generation sequencing, using small amounts of starting material and delivering reproducible gene expression profiles from challenging material, such as formalin-fixed, paraffin-embedded (FFPE) tissue. To evaluate EdgeSeq for analysis of archives of stained FFPE tissue, EdgeSeq was performed on unstained, hematoxylin and eosin (H&E)-stained, and immunohistochemistry-stained slides from patients with small-cell and non-small-cell lung cancer. Pairwise comparisons of gene expression profiles from stained and unstained slides showed higher Pearson correlation coefficients with H&E staining (0.86 to 0.97) than with immunohistochemistry staining (0.21 to 0.56). A 25-gene interferon-γ signature score from unstained slides showed a Pearson correlation coefficient of 0.92 with H&E-stained slides and a significant Spearman correlation (P = 0.0025) with immune scores. To test gene expression profiling in small samples, FFPE sample equivalents were examined from 5.0 to 0.08 mm2 of a section (5 μm thick); sample equivalents ≥0.31 mm2 showed alignment rates >69% and pairwise Pearson correlation coefficients ≥0.87. EdgeSeq can, thus, be used to profile small and H&E-stained FFPE tumor specimens to obtain biomarker data from limited tissue in oncology clinical trials and enable research into tumor microenvironment and immune cell engagement with tumors at the locoregional level.
Copyright © 2019 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31255795     DOI: 10.1016/j.jmoldx.2019.04.011

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  8 in total

1.  SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery.

Authors:  Siwen Hu-Lieskovan; Srabani Bhaumik; Kavita Dhodapkar; Jean-Charles J B Grivel; Sumati Gupta; Brent A Hanks; Sylvia Janetzki; Thomas O Kleen; Yoshinobu Koguchi; Amanda W Lund; Cristina Maccalli; Yolanda D Mahnke; Ruslan D Novosiadly; Senthamil R Selvan; Tasha Sims; Yingdong Zhao; Holden T Maecker
Journal:  J Immunother Cancer       Date:  2020-12       Impact factor: 13.751

2.  Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial.

Authors:  Thomas Powles; Srikala S Sridhar; Yohann Loriot; Joaquim Bellmunt; Xinmeng Jasmine Mu; Keith A Ching; Jie Pu; Cora N Sternberg; Daniel P Petrylak; Rosa Tambaro; Louis M Dourthe; Carlos Alvarez-Fernandez; Maureen Aarts; Alessandra di Pietro; Petros Grivas; Craig B Davis
Journal:  Nat Med       Date:  2021-12-10       Impact factor: 53.440

3.  Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial.

Authors:  Thomas Powles; Kobe C Yuen; Silke Gillessen; Edward E Kadel; Dana Rathkopf; Nobuaki Matsubara; Charles G Drake; Karim Fizazi; Josep M Piulats; Piotr J Wysocki; Gary L Buchschacher; Boris Alekseev; Begoña Mellado; Bogusława Karaszewska; Jennifer F Doss; Grozdana Rasuo; Asim Datye; Sanjeev Mariathasan; Patrick Williams; Christopher J Sweeney
Journal:  Nat Med       Date:  2022-01-10       Impact factor: 87.241

4.  Transcriptome and unique cytokine microenvironment of Castleman disease.

Authors:  Anna Wing; Jason Xu; Wenzhao Meng; Aaron M Rosenfeld; Elizabeth Y Li; Gerald Wertheim; Michele Paessler; Adam Bagg; Dale Frank; Kai Tan; David T Teachey; Megan S Lim; Eline Luning Prak; David C Fajgenbaum; Vinodh Pillai
Journal:  Mod Pathol       Date:  2021-10-22       Impact factor: 8.209

5.  Evaluation of the EdgeSeq Precision Immuno-Oncology Panel for Gene Expression Profiling From Clinical Formalin-Fixed Paraffin-Embedded Tumor Specimens.

Authors:  Yang Shi; Xiaopeng Ma; Wei Shen; Tengfei Liu; Liang Liang; Silu Liu; Zhirong Shen; Yun Zhang; Pei Zhang
Journal:  Front Cell Dev Biol       Date:  2022-05-27

6.  CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma.

Authors:  Pedro Rocha; Ruth Salazar; Jiexin Zhang; Debora Ledesma; Jose L Solorzano; Barbara Mino; Pamela Villalobos; Hitoshi Dejima; Dzifa Y Douse; Lixia Diao; Kyle Gregory Mitchell; Xiuning Le; Jianjun Zhang; Annikka Weissferdt; Edwin Parra-Cuentas; Tina Cascone; David C Rice; Boris Sepesi; Neda Kalhor; Cesar Moran; Ara Vaporciyan; John Heymach; Don L Gibbons; J Jack Lee; Humam Kadara; Ignacio Wistuba; Carmen Behrens; Luisa Maren Solis
Journal:  Cancer Immunol Immunother       Date:  2021-01-08       Impact factor: 6.968

7.  Pan-cancer gene expression analysis of tissue microarray using EdgeSeq oncology biomarker panel and a cross-comparison with HER2 and HER3 immunohistochemical analysis.

Authors:  Koichiro Inaki; Tomoko Shibutani; Naoyuki Maeda; Serenella Eppenberger-Castori; Stefan Nicolet; Yuki Kaneda; Kumiko Koyama; Yang Qiu; Kenichi Wakita; Masato Murakami
Journal:  PLoS One       Date:  2022-09-22       Impact factor: 3.752

8.  Antigen-agnostic microfluidics-based circulating tumor cell enrichment and downstream molecular characterization.

Authors:  Evan N Cohen; Gitanjali Jayachandran; Max R Hardy; Ananya M Venkata Subramanian; Xiangtian Meng; James M Reuben
Journal:  PLoS One       Date:  2020-10-23       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.